The leukaemogenic potency and biological function of subclonal FLT3-ITD alleles that are overexpressed requires further investigation in order to explore the role of this abnormality in iAMP21-ALL and assess the utility of such novel targeted therapies in the treatment of this disease. This evidence concerns the gene FLT3 and acute lymphoblastic leukemia.